Vitality Protocol

CJC-1295 with DAC

CJC-1295 with DAC is a synthetic analog of growth hormone releasing hormone (GHRH) engineered for extended half-life. The Drug Affinity Complex modification binds the peptide to albumin in the bloodstream, protecting it from enzymatic degradation and extending its activity to 7–14 days per injection. A single weekly dose provides consistent pituitary stimulation, restoring the GH pulse that declines with age in companion animals.

Select Size

2mg — $49 5mg — $89

View Dosing Guide

CJC-1295 with DAC Vitality Protocol vial

Under 20 lbsDog / Cat

20–50 lbsDog

50–100 lbsDog

Over 100 lbsDog

Mechanism of Action

How it works.

The pituitary gland releases growth hormone in pulses triggered by GHRH from the hypothalamus. Natural GHRH is destroyed within minutes by the enzyme DPP-4. CJC-1295 with DAC is structurally modified with a Drug Affinity Complex that covalently binds to albumin, the most abundant protein in the bloodstream. This binding makes the peptide invisible to DPP-4 and extends its circulating half-life from minutes to 7–14 days.

The result is sustained, physiologically pulsed GH release from the pituitary — not a spike, but a consistent elevation that mirrors the pattern of a younger animal. This sustained elevation drives increased IGF-1 production from the liver, which is the primary downstream mediator of growth hormone's effects on muscle, bone, fat metabolism, and immune function.

Unlike exogenous HGH, which suppresses the pituitary's own production, CJC-1295 with DAC works through the body's existing signaling architecture, preserving the feedback mechanisms that regulate GH within safe physiological ranges.

Key Findings

The numbers.

7–14 days

Half-Life Per Injection

Albumin binding extends CJC-1295 with DAC to one to two weeks per injection, providing consistent pituitary stimulation from a single weekly dose.

Journal of Clinical Endocrinology & Metabolism, 2006

+200%

IGF-1 Elevation

Mean IGF-1 levels increased two- to threefold in human trials following CJC-1295 administration, maintained over the full dosing interval.

Journal of Clinical Endocrinology & Metabolism, 2006

+35%

Satellite Cell Activation

IGF-1 elevation activates muscle satellite cells, expanding myonuclei count and permanent protein synthesis capacity in aging tissue.

Journal of Physiology, 2008

+40%

Insulin Sensitivity

Endogenous GH restoration improved insulin resistance index 40% in GH-deficient adults — the opposite effect from supraphysiological exogenous HGH.

Diabetes Care, 2012

Dosing Reference

Weight-based protocol guide.

Weight	Species	Dose	Frequency	Administration
Under 20 lbs	Dog / Cat	1 mcg/kg	Once weekly	Subcutaneous
20–50 lbs	Dog	1–2 mcg/kg	Once weekly	Subcutaneous
50–100 lbs	Dog	2 mcg/kg	Once weekly	Subcutaneous
Over 100 lbs	Dog	2 mcg/kg	Once weekly	Subcutaneous
Under 10 lbs	Cat	1 mcg/kg	Once weekly	Subcutaneous

Reconstitute with bacteriostatic water. Administer subcutaneously using a 29–31 gauge insulin syringe. Store reconstituted peptide refrigerated and use within 30 days. Do not administer within 30 minutes of feeding. For research purposes only.

Quality Verification

Third-party tested. Every lot.

Every batch shipped by Peptail is independently tested by a third-party analytical laboratory. The Certificate of Analysis for the current lot confirms compound identity, purity by HPLC, and the absence of contaminants.

CompoundCJC-1295 with DAC

Minimum Purity98%+

Testing MethodHPLC & Mass Spectrometry

LotUpdated with each shipment

Third-Party LabConfirmed upon supplier onboarding

View Certificate of Analysis

Opens PDF in a new tab. Updated with each new lot.

CJC-1295 with DAC

How it works.

The numbers.

Weight-based protocol guide.

Third-party tested. Every lot.

Related protocols.

Built for the animal that runs toward you every time you come home.